Indication IV

Therapy: Porosome Reconstitution for iPSC beta islets for Type I and two Small Molecules for Type II diabetes.

Status:  Preclinical. Porosome reconstitution in beta cells to optimize insulin secretion achieved. The mechanism of action of two small molecules determined using AI. in vitro biochemical and molecular approaches advanced.

Commercial Value: For Type I diabetes, optimizing the glucose-stimulated insulin secretion (GSIS) of induced pluripotent stem cell (iPSC)-derived beta cells holds significant commercial value, as it directly translates to functional, "cured" patient outcomes, shifting the market from chronic insulin management to potentially one-time curative therapies. Improved GSIS  ensures that transplanted cells behave like healthy islets, mitigating risks  of hypoglycemia and providing superior, long-term glycemic control [Front. Biomater. Sci., 18 March 2025, Sec. Bioinspired and Complex Materials, Volume 4 - 2025 | https://doi.org/10.3389/fbiom.2025.1524518]. 

The U.S. market for T1D is projected to reach $24.36 billion by 2031, with a high demand for solutions that move beyond traditional, donor-dependent transplants. for Type II diabetes, small molecules that increase glucose-stimulated insulin secretion (GSIS) in pancreatic beta-cells possess high commercial value, driven by the need for oral alternatives to injectable incretins (GLP-1 receptor agonists) and the goal of restoring functional beta-cell mass in diabetes. The market for non-insulin diabetes therapeutics is projected to grow significantly, with a high demand for agents that offer better glycemic control, safety, and weight management. Market revenues estimated to rise from $75.09 billion in 2025 to $132.36 billion by 2034, indicating immense commercial opportunities for novel, effective oral compounds.